Showing results (1981-1990 of 2,003) with videos related to

Sort By:
Pageof 201
Clinical Lung Cancer|February 28, 2025
Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (≥50%) PatientsAdriana P C Barrichello, Arielle Elkrief, Biagio Ricciuti, et al.
Cancer Letters|June 5, 2024
Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort studyKylie Fletcher, Alessio Cortellini, Teja Ganta, et al.
Cerebrovascular Diseases (Basel, Switzerland)|July 19, 2006
Intracranial haemorrhage in patients on antithrombotics: clinical presentation and determinants of outcome in a prospective multicentric study in Italian emergency departmentsG Baldi, F Altomonte, M Altomonte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 11, 2024
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung CancerBiagio Ricciuti, Giuseppe Lamberti, Sreekar R Puchala, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|December 3, 2019
Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancerAngela L McCleary-Wheeler, Ryan M Carr, Shanique R Palmer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 29, 2023
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLCJoao V Alessi, Xinan Wang, Arielle Elkrief, et al.
JAMA Oncology|November 4, 2021
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort StudyCaroline A Nebhan, Alessio Cortellini, Weijie Ma, et al.
Dermatology (Basel, Switzerland)|February 10, 2015
Differences in clinicopathological features and distribution of risk factors in Italian melanoma patientsP Fava, C Astrua, A Chiarugi, et al.
Endocrine|January 4, 2024
Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national databaseFrancesco Panzuto, Stefano Partelli, Davide Campana, et al.
JAMA Oncology|June 16, 2022
Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression LevelsBiagio Ricciuti, Xinan Wang, Joao V Alessi, et al.
Pageof 201